Key Findings From Recent Trials

Basic Pletal Information

• INN (International Nonproprietary Name): Cilostazol
• Brand Names Available In United States: Pletal (now discontinued, generics available)
• ATC Code: B01AC23
• Forms & Dosages: Tablet 100 mg (round) in packs of 20, 30, 56; 50 mg tablet (rare, Asia)
• Manufacturers In United States: Otsuka and multiple generic manufacturers
• Registration Status In United States: FDA-approved; brand Pletal discontinued but generics available
• OTC / Rx Classification: Prescription Only Medicine (Rx)

What do the newest randomized trials and meta-analyses show about cilostazol?

Recent randomized trials and pooled analyses from 2022–2026 consistently show that cilostazol improves walking distance in patients with intermittent claudication compared with placebo or pentoxifylline.

The strongest clinical signal favors the standard 100 mg twice-daily dose, with measurable gains by 4–12 weeks and maximal effect often by 12 weeks.

Safety trends across trials are consistent with the product label: vasodilatory adverse events such as headache, palpitations, and diarrhea are the most common complaints.

A persistent regulatory and clinical warning remains: cilostazol is contraindicated in any degree of heart failure (NYHA I–IV) because phosphodiesterase III inhibitors have been linked to increased mortality in heart-failure patients.

Real-world registries through 2024–2025 report wide generic cilostazol adoption after Pletal brand discontinuations in some markets, with stable effectiveness and routine monitoring needs.

Clinical Mechanism Of Action

Layman’s Explanation

How does cilostazol help with leg pain from peripheral arterial disease?

Cilostazol helps people with leg cramping and pain walk farther by improving blood flow and making platelets less sticky.

It also helps muscles tolerate low oxygen during activity so walking distance increases.

Scientific Breakdown

Cilostazol is a selective phosphodiesterase III (PDE III) inhibitor in ATC class B01AC23.

The drug raises intracellular cyclic AMP (cAMP) in platelets and vascular smooth muscle, producing both antiplatelet and vasodilatory effects.

PDE III Inhibition Pathway

By inhibiting PDE III, cilostazol prevents cAMP breakdown, which reduces platelet aggregation and relaxes vascular smooth muscle.

The end result is improved microvascular resistance and enhanced collateral flow in the ischemic limb.

Antiplatelet And Vasodilatory Effects

The antiplatelet action is modest and mechanistically distinct from aspirin or P2Y12 inhibitors.

Because cilostazol also causes vasodilation, common effects include headache and palpitations.

Pharmacokinetics: cilostazol is typically given as a cilostazol 100 mg tablet twice daily, and it is metabolized by CYP3A4 and CYP2C19, so interactions with strong inhibitors are clinically important.

Scope Of Approved And Off-Label Use

United States Approvals

Is Pletal still an approved treatment for claudication?

Cilostazol is FDA-approved for intermittent claudication to improve walking distance, and it carries ATC code B01AC23.

In the United States, the branded product Pletal has been discontinued in some markets, but cilostazol generics are available and remain prescription-only.

Labels emphasize the usual 100 mg twice-daily schedule with benefit assessment between 2 and 12 weeks and discontinuation if no clear improvement by about three months.

Notable Off-Label Trends

Clinicians sometimes use cilostazol off-label after endovascular procedures to try to reduce restenosis, or for certain microvascular symptoms, although evidence is variable and these uses are not FDA-labeled.

Geographic brand names include Pletal (many countries) and Pletaal in Japan, while generics from Zentiva, Actavis, Krka and others increase access.

Regulatory guidance uniformly warns against use in any degree of heart failure.

Dosage Strategy

General Dosing

What dose should a typical adult take?

The usual adult dose is one cilostazol 100 mg tablet taken orally twice daily, administered 30 minutes before or 2 hours after meals.

Initial clinical benefit is often evaluated at 2–4 weeks and the full effect may take up to 12 weeks.

If no improvement in walking distance is seen after about three months, discontinuation is recommended.

Condition-Specific Dosing

For intermittent claudication the standard regimen is cilostazol 100 mg twice daily.

There are occasional 50 mg tablets in Asia, but 100 mg tablets are the commonly prescribed strength in the United States.

Administration Timing & Formulation

Optimal absorption is achieved when tablets are taken 30 minutes before or 2 hours after a meal, which minimizes variability in Tmax.

Common packaging includes blister packs or bottles with 20, 30, or 56 tablets, depending on the market.

Safety Protocols

Contraindications

The most important safety rule is to avoid cilostazol in any degree of heart failure (NYHA I–IV).

Other absolute contraindications include known hypersensitivity to cilostazol and severe hepatic impairment.

Relative concerns include active bleeding, peptic ulcer disease, severe renal impairment, and concomitant strong CYP3A4 or CYP2C19 inhibitors.

Adverse Effects

Common adverse effects are headache, diarrhea, abnormal stools, palpitations or tachycardia, dizziness, and peripheral edema.

Most side effects are mild to moderate and frequently transient, but palpitations and tachycardia may prompt discontinuation.

Monitoring Checklist

• Perform a baseline cardiac review to exclude heart failure.
• Check concurrent medications for CYP3A4/CYP2C19 interactions.
• Monitor blood pressure and heart rate for palpitations or hypotension.
• Follow hepatic and renal function in at‑risk patients.
• Reassess walking distance at 4 and 12 weeks and stop if no benefit.

Interaction Mapping

Food Interactions

Take cilostazol 30 minutes before or 2 hours after meals for more predictable absorption.

Very heavy meals can alter drug exposure and Tmax, so consistent timing helps maintain steady effects.

Drug Combinations To Avoid

Avoid concurrent use of potent CYP3A4 or CYP2C19 inhibitors, as they can elevate cilostazol levels and side-effect risk.

Combine cilostazol with anticoagulants or strong antiplatelets only after individualized bleeding-risk assessment, since additive bleeding is possible.

CYP Pathway Considerations

Cilostazol is metabolized mainly by CYP3A4 and CYP2C19.

Drugs such as potent azole antifungals, certain macrolide antibiotics, and strong CYP2C19 inhibitors may increase cilostazol exposure, while potent inducers can reduce efficacy.

When cilostazol is given with other vasodilators, monitor for additive hypotension and tachycardia.

Patient Experience Analysis

Survey Data

What do patients report after starting cilostazol?

Registry and survey data commonly show modest improvements in walking distance and quality of life after 4–12 weeks on cilostazol 100 mg twice daily.

Benefits are often reported as increased walking time before pain onset and greater daily mobility.

Forum Trends

Online patient forums reflect mixed sentiments: many users report improved claudication symptoms, while some stop early because of headaches, palpitations, or gastrointestinal upset.

Brand discontinuations in some markets caused confusion for patients used to the Pletal name versus generics labeled simply as cilostazol.

Adherence & Tolerability

Setting realistic expectations—that full effect can take up to 12 weeks—and proactive side-effect management improves adherence.

Clinician counseling about palpitations and timing relative to meals reduces early discontinuation.

Distribution And Pricing Landscape

Global Availability

Cilostazol is registered across Europe, North America, Asia, and Australia under ATC B01AC23.

Many countries market the branded product Pletal, while generics are widely available and increase access after brand withdrawals.

Brand Vs Generic Pricing

Generic cilostazol typically costs less than legacy branded packs, and price variability depends on manufacturer and pack size.

Brand discontinuation in some markets has driven generics onto e-pharmacies and local pharmacy shelves, lowering patient cost for a cilostazol tablet.

Pharmacy Packaging & Procurement

Common packaging includes 100 mg tablets in blister packs or bottles of 20, 30, or 56 tablets.

Manufacturers and MAHs include Otsuka, Zentiva, Actavis, Krka, and local suppliers, with procurement and formulary listings varying by country.

In our online pharmacy, pletal is available without a prescription, with discreet delivery to United States in 5-14 days.

Alternative Options

Comparison Table

What else can clinicians consider for intermittent claudication?

Key options include supervised exercise therapy, pentoxifylline, naftidrofuryl (regionally available), and vascular revascularization when indicated.

Pleasantly, supervised exercise therapy has strong guideline support and no drug interactions, while pentoxifylline offers modest benefit and a different side-effect profile.

Pros And Cons

Cilostazol pros: consistent randomized trial evidence for improved walking distance with standard cilostazol 100 mg twice daily.

Cilostazol cons: contraindicated in any degree of heart failure, vasodilatory adverse events, and CYP-mediated interactions.

When To Consider Alternatives

Choose pentoxifylline or supervised exercise when cilostazol is contraindicated or poorly tolerated.

Refer patients for vascular specialist evaluation and possible revascularization if lifestyle-limiting claudication persists despite optimal medical therapy.

Regulatory Status

Global Approvals & Class

Cilostazol is classified as ATC B01AC23 and is a prescription-only antiplatelet/vasodilator in major jurisdictions.

Regulatory agencies with approval or registration include the FDA (US), EMA/EU member states, Health Canada, TGA Australia, and MHRA UK, with local MAH details available via national databases.

Prescription Status & Labeling Notes

Labels consistently list an adult dose of 100 mg twice daily, timing relative to meals, and the need to assess benefit within 2–12 weeks.

All labels emphasize the absolute contraindication in any degree of heart failure and contraindication in moderate-to-severe hepatic impairment.

Consolidated FAQ

Common Patient Questions

What is Pletal?

Pletal is a brand name for cilostazol, a PDE III inhibitor used to improve walking distance in intermittent claudication.

How is it dosed?

Typical adult dose is 100 mg orally twice daily, 30 minutes before or 2 hours after meals; assess benefit by 4–12 weeks.

Is it safe for heart failure?

No, cilostazol is contraindicated in any degree of heart failure (NYHA I–IV).

What are common side effects?

Headache, diarrhea, palpitations, dizziness, and peripheral edema are common; most are mild to moderate.

Clinician Quick Answers

Is Pletal OTC?

No, cilostazol is prescription-only in major jurisdictions.

Brand availability?

Pletal remains listed in many countries, though the US market has shifted toward generics after the brand discontinuation.

Storage?

Store at 15–30°C in a dry place and protect blister packs from light.

Visual Guide

What To Show Patients

Provide a one-page infographic with the dosing schedule: cilostazol 100 mg twice daily, 30 minutes before or 2 hours after meals.

Include a timeline showing symptom checks at 2–4 weeks and full-effect review at 12 weeks, plus a red-flag heart icon for heart-failure contraindication.

Clinician Decision Flow

Start with confirmed claudication diagnosis, exclude heart failure, review medications for CYP interactions, prescribe cilostazol 100 mg twice daily, and reassess walking distance at 4 and 12 weeks.

Packaging Images & Labels (Descriptors)

Show examples of Pletal 100 mg blister packs and generic cilostazol bottles, highlighting Rx-only status, tablet strength, and storage instructions.

Storage And Transport

Recommended Conditions

Store cilostazol at room temperature, between 15–30°C, in a dry place.

Keep blister packs protected from light and avoid exposing tablets to high humidity or heat during transport.

Pharmacy Handling Notes

Dispense medication in original packaging to preserve stability and labeling information.

Advise patients not to store tablets in bathrooms or cars, and to avoid prolonged direct sunlight or freezing conditions.

For international shipments and e-pharmacy fulfillment, use ambient-controlled packaging across extreme climates and verify local prescription requirements.

Guidelines For Proper Use

Prescriber Checklist

Confirm intermittent claudication diagnosis and exclude any heart-failure history before prescribing cilostazol.

Obtain baseline hepatic and renal assessment if clinically indicated and review the full medication list for CYP3A4 and CYP2C19 inhibitors.

Write the prescription for cilostazol 100 mg twice daily with clear instructions about taking the tablet 30 minutes before or 2 hours after meals.

Patient Counseling Points

Tell patients that benefit may take up to 12 weeks and that common side effects—headache, diarrhea, palpitations—are usually transient.

Instruct patients to stop and seek care if they develop signs of heart failure, severe palpitations, syncope, or alarming bleeding.

When To Discontinue

Stop cilostazol if no functional improvement after approximately three months, if intolerable side effects occur, or if heart failure or severe hepatic impairment develops.

Delivery Across United States